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Innate-Type and Acquired-Type
Allergy Regulated by IL-33
Tomohiro Yoshimoto1 and Kazufumi Matsushita1
ABSTRACT
We propose two types of allergic response: IgE-dependent and IgE-independent, and designate these as
‘acquired-type allergy’ and ‘innate-type allergy’, respectively. IL-33 stimulates both innate (basophils, mast
cells, or group 2 innate lymphoid cells) and acquired (Th2 cells) allergy-related cells to induce andor augment
Th2 cytokine production, which leads to eosinophilic inflammation in vivo. Thus, IL-33 is an essential regulator
for both ‘innate-type allergy’ and ‘acquired-type allergy’, and might be an attractive therapeutic target for allergic
diseases.
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INTRODUCTION
It is well documented that basophils and mast cells
release large amounts of IL-4 and IL-13 after cross-
linkage of the IgE receptor, Fcε receptor I (FcεRI),
by complexes of antigen plus antigen-specific IgE.1,2
IL-4 initiates and promotes Th2 responses and addi-
tionally activates these effector cells,3 while IL-13 con-
tributes to the development of allergic responses by
inducing mucus formation and eosinophilic infiltra-
tion via the production of eotaxin.4 Upon linkage of
FcεRI, basophils and mast cells produce various
other bioactive chemical mediators such as histamine
and lipid metabolites.1 Thus, cross-linkage of FcεRI is
associated with the development of ‘acquired-type al-
lergy’, and IgE antibody is therefore an essential
molecule in this process (Fig. 1 left).
In contrast, we identified a type of allergy that does
not require IgE antibody. Transgenic mice over-
expressing IL-18 in keratinocytes spontaneously de-
velop atopic dermatitis even in the absence of STAT6
activation, which is required for Th2 cell development
and IgE production.5 Moreover, cultured bone-
marrow-derived murine basophils and mast cells ex-
press IL-18Rα chain and produce Th2 cytokines (IL-4,
IL-6, IL-9 and IL-13) and histamine in response to
stimulation with IL-3 and IL-18, even without FcεRI
cross-linkage6 (Fig. 1 right). In addition, both baso-
phils and mast cells express ST2 (IL-33Rα chain), re-
cently identified as the receptor for IL-33, a member
of the IL-1 family.7 Like IL-18, IL-33 can stimulate ba-
sophils and mast cells to produce Th2 cytokines with-
out cross-linkage of FcεRI.7 From these results, we
concluded that there are two types of allergy, one of
which requires allergen and IgE antibody and an-
other that does not require these molecules. We have
designated these two types of allergy, ‘acquired-type
allergy’ and ‘innate-type allergy’.8 IL-18 and IL-33 are
essential regulators for ‘innate-type allergy’ (Fig. 1
right).
In addition, basophils can produce Th2 cytokines
in response to proteases from allergens and
helminths, or pathogen-associated molecular patterns
(PAMPs), via Toll-like receptors (TLRs). Papain, a
cysteine protease allergen, can strongly induce the
expression of transcripts encoding Th2 cytokines (IL-
4, IL-6 and IL-13), thymic stromal lymphopoietin
(TSLP) and CC chemokine ligand (CCL)1, which are
associated with Th2 cell differentiation and recruit-
ment, in bone-marrow-derived murine basophils with-
out cross-linkage of FcεRI.9 It has been also reported
that bone-marrow-derived murine basophils selec-
tively express TLR 1, 2, 4 and 6 and produce signifi-
cant amounts of Th2 cytokines in response to IL-3
plus peptidoglycan or IL-3 plus lipopolysaccharide via
TLR2 or TLR4, respectively, in the absence of FcεRI
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Fig.　1　Acquired-type allergy and innate-type allergy. IgE antibody is an essential molecule in allergy in-
duced by mast cells or basophils stimulated by complexes of antigen and antigen-specifi c IgE that inter-
act with FcεR1 to stimulate the production of Th2 cytokines and histamine. In contrast, IL-18/IL-33 stimu-
lation of basophils induces the production of Th2 cytokines without FcεRI cross-linkage. Furthermore, 
basophils produce Th2 cytokines in an IgE-independent manner after exposure to components of aller-
gens and helminths via unknown receptors or after stimulation by pathogen-associated molecular pat-
terns (PAMPs) via Toll-like receptors (TLRs). Furthermore, group 2 innate lymphoid cells (ILC2s) produce 
large amounts of IL-5 and IL-13 in response to epithelial cell-derived cytokines, IL-33, IL-25 and TSLP. 
Because of the relative involvement of the acquired/innate immune systems, we propose the former type 
of allergic response be termed ‘acquired-type allergy’ and the latter ‘innate-type allergy’.
cross-linkage10 (Fig. 1 right). These results suggest
basophils stimulated by protease allergen and
PAMPs may play a key role in the induction of innate-
type allergy.
Furthermore, recently identified natural helper
cells,11 nuocytes,12 and innate helper 2 (IH2) cells,13
currently termed group 2 innate lymphoid cells
(ILC2s)14 that are negative for lineage markers, ex-
press ST2 and produce large amounts of IL-5 and IL-
13 in response to IL-33 as well as IL-25 and TSLP. All
of these cytokines (IL-25, IL-33 and TSLP) including
IL-18 are epithelial cell-derived cytokines and are es-
sential regulators of innate-type allergy. Furthermore,
they are a link between innate-type allergy and
acquired-type allergy.
This review describes the nature of IL-33 and then
provides details of ‘innate-type’ or ‘acquired-type’ al-
lergic diseases regulated by IL-33, based mainly on
the findings of our research group.
THE NATURE OF IL-33
EXPRESSION, LOCALIZATION, AND SECRE-
TION OF IL-33
IL-33, the latest member of the IL-1 family is the
ligand for ST2 (IL-33Rα)15 and shares a signaling
pathway with IL-1 and IL-18.15-17 However, unlike IL-1
and IL-18, protein maturation is not necessary for IL-
33 bioactivity. Full-length IL-33, a 30-kDa protein, is
biologically active.18,19 IL-33 is most likely released
through cell necrosis or injury rather than cleavage
by caspase.19 Thus, IL-33 is similar to an alarmin or
damage-associated molecular patterns (DAMPs),
such as IL-1α and high mobility group box 1
(HMGB1), which are endogenous proinflammatory
factors released from damaged cells.17,20,21 However,
necrotic cell death may not be the only way of releas-
ing IL-33. An aeroallergen, the fungus Alternaria al-
ternata, has been identified as an inducer of IL-33 re-
lease in the absence of cell death. Alternaria extract
stimulation induces IL-33 secretion from in vitro cul-
tured epithelial cells via the acute accumulation of ex-
tracellular ATP.22
IL-33 was originally identified as a nuclear factor
protein in endothelial cells of high endothelial ve-
nules (HEV)23; hence, it was initially called NF-HEV.
Indeed, IL-33 is constitutively expressed and localized
in the nucleus of epithelial and endothelial cells from
various tissues with a few exceptions.21,24 Thus, it was
considered that IL-33 functioned as a nuclear factor.
However, very little is known at present regarding
the role of IL-33 as a nuclear factor.
IL-33 in Allergic Diseases
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Fig.　2　Multifaceted bioactivity of IL-33. Various lymphocytes and myeloid cells 
express ST2 and can respond to IL-33 to promote the expression and/or produc-
tion of various cytokines and functions. In particular, IL-33 is a potent inducer of 
Th2 cytokines from allergy-related cells (Th2 cells, basophils, mast cells, eosino-
phils, and group 2 innate lymphoid cells [ILC2s]). This broad array of effector func-
tions of IL-33 on various cells indicates the importance and complex involvement 
of IL-33 in a wide range of diseases.
TARGET CELLS AND THEIR RESPONSES TO IL-
33
ST2 (IL-33Rα) is expressed on a variety of cell types,
epithelia, and endothelia in various tissues, fibro-
blasts, T cells, B-1 cells, basophils, mast cells, eosino-
phils, neutrophils, natural killer cells, invariant natu-
ral killer T cells, monocytes, macrophages, dendritic
cells, and ILC2s16,17 (Fig. 2). Therefore, these cells
respond to the presence of IL-33. ST2 was initially
shown to be abundant on Th2 cells25 and IL-33 is a
potent inducer of Th2 cytokines. IL-33 treatment of
Th2 cells augments IL-5 and IL-13 production.15 Simi-
larly, the culture of naive T cells with IL-33 induces
IL-5- and IL-13-, but not IL-4-, producing T cells.26 IL-
33 also potently activates innate Th2 cytokine produc-
ers. As mentioned above, IL-33 induces IL-6 and IL-13
production from basophils and mast cells in the ab-
sence of FcεRI cross-linkage.7,27-30 Eosinophils stimu-
lated with IL-5 andor GM-CSF up-regulate ST2, and
are responsible for IL-33 induced IL-4 production.31
Furthermore, IL-33 stimulates ILC2s to produce large
amounts of IL-5, IL-9, and IL-13.32 Th2 cytokines pro-
duced from innate-type cells play critical roles in the
development of IgE-independent ‘innate-type’ allergy
as well as in exacerbating IgE-dependent ‘acquired-
type’ allergy (described below in detail). Further-
more, considering type 2 inflammation, IL-33 en-
hances differentiation of alternatively activated or M2
macrophages that are characterized by the surface
expression of mannose receptor and IL-4Rα and the
production of CCL17 and CCL24. IL-33 directly in-
duces M2 macrophage differentiation from bone mar-
row cells or alveolar macrophages in concert with IL-
13.33 In addition, IL-33-activated eosinophils enhance
M2 macrophage polarization.34 IL-33 also induces
proinflammatory cytokines, such as IL-1β, IL-6, and
TNF-α, from mast cells35-37 and basophils7,29,30 as well
as the Th1 cytokine IFN-γ from NK cells and NKT
cells.29,38 IL-33 is a chemoattractant for human Th2
cells.39 Furthermore, IL-33 recruits eosinophils, baso-
phils, and neutrophils to the site of inflammation by
facilitating the production of chemokines.7,15,33,40,41
This broad array of IL-33 effector functions on vari-
ous cell types indicates the importance and complex
involvement of IL-33 in a wide range of diseases. In-
deed, IL-33 acts as an exacerbating factor in various
inflammatory diseases, such as rheumatoid arthritis
and inflammatory bowel diseases. However, reports
indicate IL-33 can improve several diseases such as
ischemic heart diseases, atherosclerosis and Al-
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Fig.　3　IL-33-mediated innate-type allergic responses in the lung. In mice 
infected with a helminth parasite or infl uenza virus, rapid IL-33 production 
by alveolar epithelial type II (ATII) cells or macrophages, respectively, stim-
ulates group 2 innate lymphoid cells (ILC2s) in the lung to produce IL-5 and 
IL-13, which results in lung eosinophilia and goblet cell hyperplasia.
zheimer’s disease.17 Considering the physiological
functions of IL-33 in target cells (Fig. 2), it plays an
important role in the pathogenesis of allergic inflam-
mation. It has been speculated that aeroallergen
(such as pollen grain or fungus)-induced IL-33 from
the nuclei of airway epithelial cells induces the re-
cruitment of allergic cells (Th2 cells, eosinophils, ba-
sophils, mast cells, or ILC2s) to the airways and
stimulates them to induce cytokines or chemokines,
which results in exacerbated allergic inflammation.
INNATE-TYPE ALLERGY REGULATED BY
IL-33
INNATE-TYPE ASTHMA
Intranasal administration of IL-33 to mice induces air-
way hyperresponsiveness (AHR), goblet cell hyper-
plasia, and airway eosinophilic infiltration by an ST2
MyD88-dependent mechanism by induction of IL-5
and IL-13 in the lungs.7 Administration of IL-33 in-
duces goblet cell hyperplasia in the airways of wild-
type mice but not in those of IL-13 deficient (IL-13--)
mice, which clearly indicates that IL-33 produces
these responses by the induction of endogenous IL-
13. Furthermore, similar treatment of RAG2-- mice,
lacking T and B cells, induced more severe AHR with
marked goblet cell hyperplasia and eosinophilic infil-
tration in the lungs. Thus, IL-33 induces asthma-like
symptoms independently of the acquired immune
system. We have designated this type of Th2 cells
IgE-independent- and IL-33-dependent asthma “inna-
te-type asthma”.7 In contrast to RAG2--mice, γc--
RAG2--mice fail to develop innate-type asthma, which
suggests that unidentified bone marrow-derived cells
are the target cells for IL-33. Indeed, recently identi-
fied innate lymphoid cells (ILC2s) have been identi-
fied as the predominant IL-5 and IL-13-producing
population induced by IL-33 in murine lungs.32
It is well known that asthma is enhanced by viral
and bacterial infections. Recently, Chang et al. re-
vealed that both ILC2s and IL-33 play an important
role in asthma-like symptoms caused by influenza vi-
rus type A (H3N1).42 They demonstrated that influ-
enza virus-induced IL-33 from alveolar macrophages
increases the number of ILC2s in the lung, which
produce IL-13 from ILC2s in response to IL-33, result-
ing in innate-type asthma (Fig. 3). These findings in-
dicate IL-33 is critically involved in the pathogenesis
of innate-type asthma, suggesting IL-33 might be a
therapeutic target for the treatment of innate-type
asthma.
PROTEASE ALLERGEN-INDUCED AIRWAY EO-
SINOPHILIA
It has been shown that intranasal administration of
papain, a cysteine protease allergen, induced IL-33-
dependent innate type eosinophilia in wild-type mice
and RAG2-- mice.43 Recently, Kamijo et al. demon-
strated that intranasal administration of papain twice
(days 0 and 7) induces eosinophilic infiltration in the
lungs and papain-specific IgE and IgG1 antibodies in
wild-type mice but not in IL-33-- mice,44 indicating
the papain-induced IL-33 production in the lung. In-
deed, papain induced IL-33 in the bronchoalveolar
lavage (BAL) fluid in a dose dependent manner.
Papain-induced IL-33 stimulated lung ILC2s to pro-
duce significant amounts of IL-5 and IL-13, resulting
IL-33 in Allergic Diseases
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in severe lung eosinophilia.44,45 Furthermore, Kamijo
et al. demonstrated that RAG2-- mice showed signifi-
cant, but less severe papain-induced airway eosino-
phila, which suggests possible cooperation of ac-
quired immune cells, such as Th2 cells, and IL-33-
mediated innate immune cells, such as ILC2s, in pro-
tease allergen-induced allergic airway inflammation.
EOSINOPHILIC PNEUMONIA
Eosinophilic pneumonia (Löffler syndrome) is a very
common complication of gastrointestinal nematode
infections, including the Strongyloides, Ascaris, and
Ancylostoma species.46 Nevertheless, the physiologi-
cal relevance and pathogenesis of eosinophilic pneu-
monia are still not thoroughly understood. Recently,
Yasuda et al. demonstrated that Strongyloides vene-
zuelensis (S. venezuelensis)-infection induces severe
eosinophilic inflammation and goblet cell hyperplasia
in the lungs. In contrast, IL-33-- mice did not develop
such allergic inflammation, indicating IL-33 has a
critical role in the induction of pulmonary eosino-
philia.41 They further demonstrated that alveolar epi-
thelial type II cells (ATII) express IL-33 protein in
their nuclei and that infection with S. venezuelensis or
intranasal administration of chitin (a polysaccharide
found on the surface of helminths) increases the
number of ATII cells and the level of IL-33 expres-
sion. S. venezuelensis infection could induce pulmo-
nary eosinophilia in RAG2--mice, suggesting the con-
tribution of IL-33-stimulated ILC2s in the induction of
pulmonary eosinophilic inflammation (Fig. 3). In-
deed, ILC2s were induced in the lung of S.
venezuelensis-infected mice in an IL-33-dependent
manner. They finally revealed that IL-33-stimulated
ILC2s protects against S. venezuelensis by inducing
pulmonary eosinophilic inflammation through the
production of IL-5 and IL-13.
These results suggest that S. venezuelensis infec-
tion provokes these alterations principally through
the action of chitin. However, the precise mechanism
whereby IL-33 is released from ATII cells by nema-
tode infection remains unclear. One report demon-
strated IL-33 release is dependent on prior production
of trefoil factor 2 (TFF2), an epithelial cell-derived re-
pair molecule, during migration through the lung by
gastrointestinal Nippostrongylus brasiliensis larvae and
that TFF2-- mice consequently show impaired Th2
responses and worm expulsion.47 Both ATII cells and
TFF2 contribute to wound healing. Thus, IL-33 re-
leased from damaged bronchial epithelial cells by
nematodes has a host defense role via ILC2s driven
by IL-5 and IL-13 production.
ACQUIRED-TYPE ALLERGY REGULATED
BY IL-33
ALLERGIC RHINITIS
Allergic rhinitis (AR) is one of the most common al-
lergic inflammatory diseases, with an incidence of
over 600 million people worldwide.48 The prevalence
of seasonal AR is increasing in the developed world.
Among allergenic weeds, ragweed pollen is common
and has been reported to be a major source of air-
borne allergenic protein in the United States and
many countries of central Europe.49 AR is divided
into two categories, seasonal and perennial AR. Nasal
responses in AR comprise two phases: IgE-dependent
early-phase responses and Th2 cytokine-dependent
late-phase responses.50 Clinical symptoms, such as
sneezing and rhinorrhea, occur because of the early-
phase responses within 5-30 min. The late-phase re-
sponses consist of congestion, fatigue and malaise at
6-24 h after exposure to an allergen. The major patho-
logical changes associated with late-phase responses
are eosinophilic accumulation into the nasal mu-
cosa.50 The mechanisms underlying the development
of bronchial asthma have been well analyzed using a
murine model. However, the precise mechanisms un-
derlying the development of nasal responses in AR
have not been clearly defined.
A previous study of ours showed that the serum
level of IL-33 is significantly elevated in Japanese pa-
tients with seasonal AR, and that there is a significant
association between susceptibility to AR and polymor-
phisms in the IL33 gene.51 However, very little is
known regarding the role of IL-33 in the development
of AR. Recently, we established a novel murine model
of ragweed pollen-specific AR and examined the
pathological role of ragweed-induced IL-33 in the de-
velopment of AR using IL-33-- mice.40 After nasal
challenge with ragweed pollen, ragweed-immunized
wild-type mice manifested early-phase (sneezing) and
late-phase (eosinophilic and basophilic accumulation)
responses. In contrast, IL-33-- and FcεRIα-- mice
failed to develop either phase of AR response. Fur-
thermore, we found that ragweed-immunized mice
but not naïve mice developed a significant and time-
dependent increase in basophil accumulation in the
nasal mucosa after ragweed exposure. In addition,
this accumulation of basophils was diminished in IL-
33-- mice, suggesting that both endogenous IL-33
and ragweed-specific Th2 immunity contribute to the
nasal accumulation of basophils in AR. IL-33 protein
is constitutively expressed in the nucleus of nasal epi-
thelial cells and is promptly released into nasal fluids
in response to nasal exposure to ragweed pollen. This
ragweed pollen-driven IL-33 is essential for the devel-
opment of sneezing and the nasal accumulation of
eosinophils and basophils by increasing histamine re-
lease and inducing the production of chemoattrac-
tants from FcεRI+ mast cells and basophils, respec-
tively. Together with the contribution of IL-33 in
stimulating eosinophils, basophils, and mast cells to
produce allergic inflammatory mediators, this proc-
ess may lead to the recurrent seizures and irrevers-
ible mucosal hypertrophy observed in AR (Fig. 4).
In humans, constitutive expression of IL-33 protein
Yoshimoto T and Matsushita K
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Fig.　4　Pathogenic role of IL-33 in allergic rhinitis. Ragweed pollen-driven endogenous 
IL-33 from nasal epithelial cells contributes to both early-phase (sneezing) and late-phase 
(nasal accumulation of eosinophils and basophils) responses in allergic rhinitis (AR) by in-
creasing histamine release and inducing the production of chemoattractants from mast 
cells and basophils, respectively. Together with the contribution of IL-33 in the stimulation 
of Th2 cells, eosinophils, basophils, and mast cells to produce allergic infl ammatory medi-
ators, this process may lead to recurrent seizures and irreversible mucosal hypertrophy in 
AR.
in the nasal epithelial cells of healthy controls has
been demonstrated as well as the down-regulated ex-
pression of IL-33 protein in the inflamed nasal epithe-
lial cells of AR patients. However, IL-33 mRNA ex-
pression in the nasal epithelial cells of AR patients is
significantly up-regulated during the pollen season,40
which indicates that enhanced extracellular IL-33 re-
lease is associated with reduced IL-33 protein expres-
sion in inflamed nasal epithelial cells. Although the
mechanism of ragweed pollen-driven IL-33 release
from nasal epithelial cells remains unclear, taken to-
gether these results indicate that IL-33 may present
an important therapeutic target for the prevention of
AR.
ATOPIC DERMATITIS
Atopic dermatitis (AD) is a major allergic disorder.
The morbidity of AD reaches 20-30% in developed
countries.52 AD is characteristic of chronic dermatitis
with severe, long-lasting itching. Clinically, eosino-
phils and mast cells accumulate in the lesional skin of
patients with AD, often with elevated peripheral
blood levels of histamine and total IgE.53 Genetic
links have been identified between AD and polymor-
phisms in the gene encoding ST2. A SNP in the distal
promoter of the ST2 gene (chromosome 2q12) is sig-
nificantly associated with AD, and there is a strong
correlation with high soluble ST2 (ST2 lacking trans-
membrane and intracellular domains) and total IgE
levels in the sera of AD patients.54 These results indi-
cate this ST2 genetic polymorphism is a candidate for
conferring susceptibility to AD. Less is known about
circulating IL-33; however, mRNA levels for IL-33 and
ST2 are substantially increased in the lesional skin of
patients with AD compared with non-lesional skin
and healthy controls. Immunohistochemical staining
revealed the numbers of IL-33+ cells were increased
in keratinocytes and in endothelial cells, whereas
those of ST2+ cells were increased in infiltrating in-
flammatory cells in the dermis of lesional skin com-
pared with non-lesional skin.55 However, it was still
unclear how IL-33 contributes to these skin inflamma-
IL-33 in Allergic Diseases
Allergology International Vol 63, Suppl 1, 2014 www.jsaweb.jp 9
Fig.　5　Pathogenic role of IL-33 in atopic dermatitis. In transgenic mice over-express-
ing IL-33 in keratinocytes, IL-33 induces the recruitment of group 2 innate lymphoid 
cells (ILC2s) in the skin and stimulates the production of IL-5 to induce eosinophil infi l-
tration in the dermis of skin. IL-33 also contributes to the induction of recruitment of 
mast cells and histamine release. Together, these processes lead to spontaneous 
itchy dermatitis.
tory conditions.
Recently, our group established transgenic mice
with skin-specific overexpression of IL-33, termed hK
14mIL33tg mice.56 IL-33 was localized in the nuclei of
the epidermis, and the intensity of staining for IL-33
was higher in hK14mIL33tg mice than in wild-type
mice. Interestingly, spontaneous itchy dermatitis de-
veloped in hK14mIL33tg mice at 6-8 weeks of age in
specific pathogen-free conditions. In the lesional skin,
the epidermis was thickened, numbers of activated
eosinophils and mast cells were increased, and blood
histamine and total IgE levels were significantly
higher than controls, traits that closely resemble the
features of atopic dermatitis. The protein concentra-
tion of IL-5 and chemokines (RANTES and eotaxin)
were markedly higher in the serum and lesional skin
from hK14mIL33tg mice than in wild-type mice. In
addition, IL-5-producing ILC2s were significantly in-
creased in the lesional skin, peripheral blood, and re-
gional lymph nodes. When anti-IL-5 antibody was ad-
ministered to hK14mIL33tg mice every 2 days for 2
weeks, dermatitis with thickened epidermis with
eosinophil infiltration was markedly improved. These
results suggest that IL-33 from epidermal keratino-
cytes induces ILC2s in the skin and stimulates their
production of IL-5, which induces AD-like dermatitis
with eosinophilic infiltrates (Fig. 5). IL-33 is involved
both in the increased numbers of mast cells in the
skin,57 and in histamine release from mast cells.40
Thus, IL-33 from epidermal keratinocytes can result
in the induction of recruitment of mast cells and his-
tamine release (Fig. 5).
AD is often associated with increased serum
allergen-specific IgE (IgE associated form); however,
about 20% of patients with clinically diagnosed AD
have no allergen-specific IgE (non-IgE associated
form).58 This form of AD might represent innate-type
AD. Further studies using hK14mIL33tg mice back-
crossed to RAG2--mice will help understand the im-
portance of IgE in AD.
CONCLUSIONS
IL-33 stimulates both innate (basophils, mast cells, or
ILC2s) and acquired (Th2 cells) allergic cells to in-
duceaugment Th2 cytokine production, which leads
to eosinophilic inflammation in vivo. Thus, IL-33 is an
essential regulator for both ‘innate-type allergy’ and
‘acquired-type allergy’, and might be an attractive
therapeutic target for allergic diseases. To accom-
plish the therapeutic application of IL-33, however, a
number of issues need to be addressed. The most im-
portant issue is to identify the exact mechanism of IL-
33 release in vivo. Currently, there is a limited under-
standing of the pathways for IL-33 release. Studies
suggest IL-33 is not released by a single mechanism,
so specific neutralizing antibodies to IL-33 or inhibi-
tors to the IL-33-signaling pathway might help treat
allergic diseases.
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